BrightEdge - American Cancer Society

Cerula Care is a behavioral health company that focuses on providing services for individuals with advanced chronic conditions. The company offers virtual care solutions, including care management, coaching, and psychiatric support, aimed at addressing mental health issues such as anxiety, depression, substance use disorder, and post-traumatic stress disorder. By leveraging these services, Cerula Care seeks to enhance behavioral health outcomes for its patients, ensuring they receive comprehensive support tailored to their specific needs.

TippingPoint Biosciences is focused on developing innovative therapeutics that address diseases caused by defects in DNA packaging, with an emphasis on conditions such as cancer and neurodegenerative disorders. Utilizing a specialized drug discovery platform, the company aims to identify new treatment options that specifically target unique genome packaging states associated with various diseases. This approach not only facilitates the treatment of cancer but also holds potential for advancing stem cell therapies by correcting dysfunctional genome packaging. Through its research and development efforts, TippingPoint Biosciences seeks to provide effective solutions for complex medical challenges.

SyzOnc is a biotechnology company focused on developing therapies for solid tumors with few effective options. It uses AI, the Cell Painting assay, and cell-based models of the tumor microenvironment to identify multi-modal cancer targets and lead compounds. The platform integrates machine learning, imaging-based phenomics, and specialized bioassays to model multiple cancer types and address cancer cell proliferation, extracellular matrix regulation, and immune evasion. The initial focus targets the Hippo pathway, an underexploited cancer pathway linked to soft-tissue sarcoma, influencing tumor growth, matrix deposition, and T cell function. The company builds proprietary tumor ecosystem models from public and private data to compare genetic and compound phenotypes and generate starting points for drug development. Founders include experts from Broad Institute and UPenn, and the company has established a laboratory space in Philadelphia to advance its platform and programs.

CellCentric Ltd. is a biotechnology company based in Cambridge, United Kingdom, focused on developing innovative cancer therapeutics. Established in 2003, the company specializes in small-molecule inhibitors targeting p300, CBP, and specific deubiquitinase enzymes, which play a crucial role in regulating gene expression in cancer cells. Its primary research program addresses prostate cancer, a significant cause of male mortality, by modulating the androgen receptor pathway and potentially overcoming resistance mechanisms found in existing treatments. Additionally, CellCentric's products have applications in treating other cancers, including non-small cell lung cancer, breast cancer, and colon cancer. The company's approach aims to provide targeted therapies for various malignancies, addressing unmet medical needs in the oncology field.